IPSET Score (ET Thrombosis Risk)
International Prognostic Score for Essential Thrombocythemia (IPSET) — thrombosis risk. Guides cytoreduction and aspirin decisions.
Score interpretation
IPSET-thrombosis < 2: thrombosis 1.03 % of patients per year (Barbui 2012).
→ Observation; aspirin 75mg (adults) if JAK2+ or cardiovascular risk factors; no cytoreduction required; 6-monthly haematology review. Children: use a children's formulary.
IPSET-thrombosis 2: thrombosis 2.35 % of patients per year.
→ Adults: Aspirin 75-100mg daily; hydroxycarbamide if high platelet count; monitor for thrombosis/haemorrhage; cardiovascular risk modification; annual haematology. Children: use a children's formulary.
IPSET-thrombosis > 2: thrombosis 3.56 % of patients per year.
→ Cytoreduction usually recommended: hydroxycarbamide first-line; pegylated interferon alfa for young patients or intolerance; aspirin 75mg daily (adults); anticoagulation if prior VTE; target platelet <400; if HU resistant: anagrelide or ruxolitinib. Children: use a children's formulary.
Interpretation bands for the IPSET-Thrombosis. Apply clinical judgement and local guidance.
References
- Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-5133.
- BSH ET Guidelines 2021. ELN Recommendations for ET 2022.
Related
Curated clinical cross-links plus same-class fallbacks.
- Baricitinib 2–4mg (Atopic Dermatitis / Alopecia Areata) · JAK inhibitor (JAK1/JAK2) — systemic immunosuppressant
- Rituximab (Haematology) · Anti-CD20 Monoclonal Antibody
- Anagrelide · Cytoreductive — Essential Thrombocythaemia
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.
